Pharvaris (PHVS)
31.60
+0.01 (0.03%)
Upcoming Events
Latest Headlines
Form 4 Pharvaris N.V. For: Jun 04 Filed by: Nijdam Anna
June 8, 2026 2:54 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Nijdam Anna
June 4, 2026 6:22 PM - SEC Filing
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026 6:50 AM - Globe NewsWire
Form 4 Pharvaris N.V. For: May 21 Filed by: Monges Viviane
May 26, 2026 5:54 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 21 Filed by: Nijdam Anna
May 26, 2026 5:45 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 21 Filed by: Nassif David W.
May 26, 2026 5:42 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Nijdam Anna
May 22, 2026 5:03 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 20 Filed by: Bjork Elisabeth
May 22, 2026 2:54 PM - SEC Filing
Form 4/A Pharvaris N.V. For: May 18 Filed by: Modig Berndt
May 22, 2026 2:41 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Nijdam Anna
May 21, 2026 5:36 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Monges Viviane
May 21, 2026 5:31 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Nassif David W.
May 21, 2026 5:27 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 18 Filed by: Modig Berndt
May 20, 2026 5:34 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Bjork Elisabeth
May 20, 2026 5:24 PM - SEC Filing
Form 144/A Pharvaris N.V. Filed by: Glassman Robert
May 20, 2026 4:31 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 15 Filed by: Glassman Robert
May 19, 2026 6:48 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 15 Filed by: Abele Stefan Andreas
May 19, 2026 6:45 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 15 Filed by: Souverijns Wim
May 19, 2026 6:43 PM - SEC Filing
Form SCHEDULE 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 5:51 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Abele Stefan Andreas
May 15, 2026 5:51 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Souverijns Wim
May 15, 2026 5:45 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
May 15, 2026 4:36 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Glassman Robert
May 15, 2026 4:19 PM - SEC Filing
Form 4 Pharvaris N.V. For: May 11 Filed by: Lu Peng
May 13, 2026 6:49 PM - SEC Filing
Pharvaris B.V. (PHVS) PT Lowered to $74 at Citizens Ahead of Phase 3 Readout in Q3
May 13, 2026 5:10 AM - StreetInsider
Form 6-K Pharvaris N.V. For: May 12
May 12, 2026 4:05 PM - SEC Filing
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 4:05 PM - StreetInsider
Form 6-K Pharvaris N.V. For: May 11
May 11, 2026 4:42 PM - SEC Filing
Form 424B5 Pharvaris N.V.
May 8, 2026 5:13 PM - SEC Filing
Pharvaris prices $115 million share offering at $29.68 per share
May 8, 2026 6:01 AM - StreetInsider
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 8, 2026 6:00 AM - Globe NewsWire
Form 4 Pharvaris N.V. For: May 01 Filed by: Lu Peng
May 5, 2026 3:51 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus
May 1, 2026 7:33 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 29 Filed by: Lesage Anne
May 1, 2026 7:31 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 29 Filed by: Lu Peng
May 1, 2026 7:10 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 22 Filed by: Schikan Johannes Gerardus Christiaan Petrus
April 24, 2026 2:09 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 22 Filed by: Lesage Anne
April 24, 2026 12:18 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 22 Filed by: Lu Peng
April 24, 2026 11:27 AM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
April 22, 2026 5:17 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
April 22, 2026 4:29 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lu Peng
April 22, 2026 4:29 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
April 22, 2026 4:29 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 16 Filed by: Lu Peng
April 20, 2026 5:39 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 16 Filed by: Modig Berndt
April 20, 2026 3:00 PM - SEC Filing
Pharvaris presents safety data on combined deucrictibant formulations
April 20, 2026 6:50 AM - StreetInsider
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026 6:50 AM - Globe NewsWire
Form 144 Pharvaris N.V. Filed by: Modig Berndt
April 16, 2026 4:16 PM - SEC Filing
Pharvaris B.V. (PHVS) PT Raised to $52 at Jones Trading
April 15, 2026 3:20 PM - StreetInsider
Form 4 Pharvaris N.V. For: Apr 14 Filed by: Nijdam Anna
April 14, 2026 5:52 PM - SEC Filing
Form 4 Pharvaris N.V. For: Apr 09 Filed by: Modig Berndt
April 10, 2026 1:43 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
April 8, 2026 4:36 PM - SEC Filing
Wolfe Research Starts Pharvaris B.V. (PHVS) at Outperform
April 8, 2026 4:32 PM - StreetInsider
Form 4 Pharvaris N.V. For: Apr 06 Filed by: Nijdam Anna
April 8, 2026 3:00 PM - SEC Filing
Pharvaris B.V. (PHVS) PT Lowered at RBC Capital; 'CHAPTER-3 Pivotal Topline In Focus For 3Q'
April 6, 2026 7:10 AM - StreetInsider
Form 4 Pharvaris N.V. For: Apr 01 Filed by: Nijdam Anna
April 3, 2026 2:07 PM - SEC Filing
Form 3/A Pharvaris N.V. For: Mar 27 Filed by: Abele Stefan Andreas
April 3, 2026 11:00 AM - SEC Filing
Oppenheimer on Pharvaris B.V. (PHVS): runway sufficient to support ops through key milestones
April 2, 2026 4:35 PM - StreetInsider
Form 20-F Pharvaris N.V. For: Dec 31
April 2, 2026 6:52 AM - SEC Filing
Form 6-K Pharvaris N.V. For: Mar 31
April 2, 2026 6:50 AM - SEC Filing
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 2, 2026 6:50 AM - Globe NewsWire
Pharvaris publishes hereditary angioedema drug study results in The Lancet
March 20, 2026 6:51 AM - StreetInsider
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026 6:50 AM - StreetInsider
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Glassman Robert
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Schikan Johannes Gerardus Christiaan Petrus
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Lesage Anne
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Abele Stefan Andreas
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Bjork Elisabeth
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Nassif David W.
March 18, 2026 2:24 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Nijdam Anna
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Monges Viviane
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Meeker David P
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Souverijns Wim
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Lu Peng
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Modig Berndt
March 18, 2026 2:23 PM - SEC Filing
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Deschoolmeester Annick
March 18, 2026 2:23 PM - SEC Filing
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Pharvaris publishes study validating patient outcomes in hereditary angioedema
March 11, 2026 6:50 AM - StreetInsider
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026 6:50 AM - Globe NewsWire
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026 6:50 AM - StreetInsider
Full Article List
